| Filed On | Filing |
|---|---|
| 22 Oct 2026 |
8-K: Regulation FD Disclosure
Targeting Metabolic Dysfunction with Novel Therapeutics October 2026 Exhibit 99.1 |
| 07 Oct 2026 | SCHEDULE 13G |
| 01 Oct 2026 | 424B5 |
| 01 Oct 2026 |
8-K: Entry into a Material Definitive Agreement
On September 30, 2026, Sagimet Biosciences Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, TD Securities (USA) LLC and Guggenheim Securities, LLC as representatives of... |
| 30 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission. |
| 30 Sep 2026 | 424B3 |
| 17 Aug 2026 |
Form 4: Kemble George, Director
Received 350,987 shares by exercise or conversion ($2.23M) · Sold 350,987 shares ($3.59M) |
| 14 Aug 2026 | 144 |
| 14 Aug 2026 | SCHEDULE 13G |
| 13 Aug 2026 | 8-K: Other Events |
| 12 Aug 2026 |
Form 4: Kemble George, Director
Received 20,206 shares by exercise or conversion ($129K) · Sold 20,206 shares ($201K) |
| 11 Aug 2026 | 144 |
| 11 Aug 2026 | 10-Q |
| 11 Aug 2026 | 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure |
| 30 Jul 2026 | SCHEDULE 13G |
| 22 Jul 2026 |
Form 4: Happel David, Director
Sold 64,051 shares ($497K) |
| 22 Jul 2026 |
Form 4: Rozek Elizabeth, Chief Legal & Admin. Officer
Sold 10,545 shares ($81.8K) |
| 22 Jul 2026 |
Form 4: Kemble George, Director
Sold 18,844 shares ($141K) |
| 21 Jul 2026 | 8-K: Regulation FD Disclosure |
| 20 Jul 2026 | 144 |
Loading...
